Search Results - "Kannan, Sadhana"

Refine Results
  1. 1
  2. 2

    Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma by Gupta, Tejpal, Kannan, Sadhana, Ghosh-Laskar, Sarbani, Agarwal, Jai Prakash

    Published in PloS one (06-07-2018)
    “…Technological advancements in treatment planning and delivery have propelled the use of intensity-modulated radiation therapy (IMRT) in head and neck squamous…”
    Get full text
    Journal Article
  3. 3

    Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis by Kalra, Babusha, Kannan, Sadhana, Gupta, Tejpal

    Published in Journal of neuro-oncology (2020)
    “…Background There exists lack of consensus worldwide regarding the most optimal adjuvant therapy regimen in elderly patients with newly-diagnosed glioblastoma…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta‐analysis by Gupta, Tejpal, Thakkar, Prafulla, Kalra, Babusha, Kannan, Sadhana

    Published in Reviews in medical virology (01-03-2022)
    “…Summary Coronavirus disease 2019 (COVID‐19) caused by the novel severe acute respiratory syndrome coronavirus 2 continues to grow and spread throughout the…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis by Gupta, Tejpal, Master, Zubin, Kannan, Sadhana, Agarwal, Jai Prakash, Ghsoh-Laskar, Sarbani, Rangarajan, Venkatesh, Murthy, Vedang, Budrukkar, Ashwini

    “…Purpose Our objective was to conduct a systematic review and meta-analysis of studies assessing the diagnostic performance of 18 F-fluorodeoxyglucose positron…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Clinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method by Narasimhan, Mythreyi, Kannan, Sadhana, Chawade, Aakash, Bhattacharjee, Atanu, Govekar, Rukmini

    Published in Journal of translational medicine (31-05-2019)
    “…SWATH-MS has emerged as the strategy of choice for biomarker discovery due to the proteome coverage achieved in acquisition and provision to re-interrogate the…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers by Palve, Vinayak, Mallick, Sanchita, Ghaisas, Gauri, Kannan, Sadhana, Teni, Tanuja

    Published in PloS one (19-11-2014)
    “…Altered expression of Mcl-1, an anti-apoptotic member of the Bcl-2 family, has been linked to the progression and outcome of a variety of malignancies. We have…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Prevention of carcinogen-induced oral cancers by polymeric black tea polyphenols via modulation of EGFR-Akt-mTOR pathway by Nimbalkar, Vaishnavi K., Gangar, Jeet, Shai, Saptarsi, Rane, Pallavi, Mohanta, Subham Kumar, Kannan, Sadhana, Ingle, Arvind, Mittal, Neha, Rane, Swapnil, Mahimkar, Manoj B.

    Published in Scientific reports (25-08-2022)
    “…The overexpression of Epidermal Growth Factor Receptor (EGFR) and dysregulation of its downstream effector pathways are important molecular hallmarks of oral…”
    Get full text
    Journal Article
  18. 18

    Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases by Shriyan, Bharati, Patil, Deepali, Gurjar, Murari, Nookala, Manjunath, Patil, Anand, Kannan, Sadhana, Patil, Vijay, Joshi, Amit, Noronha, Vanita, Prabhash, Kumar, Gota, Vikram

    Published in European journal of clinical pharmacology (01-10-2020)
    “…Purpose Patients of non–small cell lung cancer (NSCLC) with brain metastases have limited treatment options. High-dose erlotinib (HDE) and gefitinib (HDG) have…”
    Get full text
    Journal Article
  19. 19
  20. 20